#AcuteMyeloidLeukemia presents a significant unmet need, with approximately 58% of patients not responding to existing therapies. Discover more about the patient journey and the opportunities with Moleculin here: https://bit.ly/3zpqrdb
关于我们
Moleculin Biotech, Inc. (NASDAQ: MBRX) is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of highly resistant tumors and viruses. The Company’s lead program, Annamycin is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity. Annamycin is currently in development for the treatment of soft tissue sarcoma (STS) lung metastases and relapsed or refractory acute myeloid leukemia (AML). Moleculin is also engaged in the development of a portfolio of antimetabolites, including WP1122 for the potential treatment of COVID-19 and other viruses, as well as cancer indications including brain tumors, pancreatic and other cancers. Additionally, the Company is developing WP1066, an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other oncogenic transcription factors while also stimulating a natural immune response, targeting brain tumors, pancreatic and other cancers, and WP1220, an analog to WP1066, for the topical treatment of cutaneous T-cell lymphoma.
- 网站
-
https://www.moleculin.com
Moleculin Biotech, Inc.的外部链接
- 所属行业
- 制药业
- 规模
- 2-10 人
- 总部
- Houston，Texas
- 类型
- 上市公司
- 创立
- 2006
地点
-
主要
获取路线
5300 Memorial Dr
Suite 950
US，Texas，Houston，77007
Moleculin Biotech, Inc.员工
动态
-
Michael Andreeff, MD, PhD, Professor of Medicine, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center and a member of Moleculin's Scientific Advisory Board, comments on the potential of Annamycin combined with Ara-C to significantly advance the standard of care for #AcuteMyeloidLeukemia patients: https://bit.ly/3AYl0Tf
-
New preliminary clinical results show Annamycin plus Ara-C achieved 60% CR/CRi in subjects who were relapsed from or refractory to Venetoclax regimens; more than 4 times greater than published historical rates. Learn more: https://bit.ly/3AYl0Tf #AcuteMyeloidLeukemia #AML
-
Wally Klemp, Chairman and Chief Executive Officer of Moleculin, comments on the new findings supporting the ability of Annamycin to overcome resistance to Venetoclax in #AcuteMyeloidLeukemia. Read more: https://bit.ly/3AYl0Tf
-
Dr. Paul Waymack discusses Annamycin dosing, highlighting that patients are receiving higher amounts than the maximum allowed—without any heart issues. To discover more about the drug's safety, watch the full KOL event here: https://bit.ly/40sWWST #MBRX #AcuteMyeloidLeukemia
-
Preclinical data accepted for online publication at the upcoming American Society of Hematology (“ASH”) Annual Meeting reveal significant activity of Annamycin in Venetoclax resistant #AML model. For more information: https://bit.ly/3AYl0Tf #AcuteMyeloidLeukemia #ASH24
-
Moleculin today announced new findings supporting the ability of Annamycin to overcome resistance to Venetoclax in #AcuteMyeloidLeukemia. For details: https://bit.ly/3AYl0Tf
-
Watch the recent Virtual Investor “What This Means” segment, where Moleculin management discusses the amended clinical trial protocol for the pivotal MIRACLE Phase 3 R/R #AcuteMyeloidLeukemia trial. Watch it here: https://bit.ly/3Z4UroF
-
Moleculin's Phase 3 R/R #AcuteMyeloidLeukemia pivotal trial is on track to treat its first patient in the first quarter of 2025. The recently announced amended protocol accelerates unblinding of preliminary primary efficacy data (CR) and safety/tolerability of the three arms at first 45 subjects in the MIRACLE trial. Learn more: https://bit.ly/3UP5wI5
-
Dr. Michael Andreef provides valuable insights into the significance of measuring residual disease in assessing treatment success for #AML. Check out the full KOL event to learn more: https://bit.ly/40sWWST #MBRX #Oncology #AcuteMyeloidLeukemia